

**Supplemental Table S1.** Characteristics of pediatric patients.

Characteristics	Overall (n=340)	Responder s(n=270)	Non- responders (n=70)	<i>p</i> value
Sex				
Male, n (%)	205 (60.3%)	168 (82.0%)	37 (18.0%)	0.171
Female, n (%)	135 (39.7%)	102 (75.6%)	33 (24.4%)	
Age (years)				
At diagnosis, median (IQR, range)	11.2 (4.0, 0.7-17.3)	11.2 (3.8, 0.9-17.3)	11.0 (5.8, 0.7-16.0)	0.109
At start of treatment, median (IQR, range)	12.2 (4.1, 1.1-17.5)	12.3 (4.1, 1.4-17.5)	12.0 (4.3, 1.1-17.3)	0.251
Months from diagnosis to initiation of therapy, median (IQR, range)	6.1 (15.9, 0.0-129.6)	6.1 (15.3, 0.0-129.6)	8.9 (18.2, 0.0-125.8)	0.202
Type of IBD				
CD, n (%)	240 (70.5%)	201 (83.8%)	39 (16.3%)	<b>0.012</b>
UC, n (%)	93 (27.4%)	63 (67.7%)	30 (32.3%)	
IC, n (%)	7 (2.1%)	6 (85.7%)	1 (14.3%)	
First or second biological treatment				
First, n (%)	318 (93.5%)	259 (81.4%)	59 (18.6%)	<b>0.001</b>
Second, n (%)	22 (6.5%)	11 (50.0%)	11 (50.0%)	
Drug				
Infliximab, n (%)	228 (67.1%)	185 (81.1%)	43 (18.9%)	0.318
Adalimumab, n (%)	112 (32.9%)	85 (75.9%)	27 (24.1%)	
Concomitant immunomodulator (n=330)				
Yes, n (%)	286 (86.7%)	229 (80.1%)	57 (19.9%)	0.843
No, n (%)	44 (13.3%)	36 (81.8%)	8 (18.2%)	
Type of immunotherapy (n=283)				
Azathioprine, n (%)	266 (81.6%)	215 (80.8%)	51 (19.2%)	0.947
Mercaptopurine, n (%)	3 (0.9%)	2 (66.7%)	1 (33.3%)	
Methotrexate, n (%)	14 (4.3%)	10 (71.4%)	4 (28.6%)	

Bold, *P* value < 0.05; IQR, Interquartile range; CD, Crohn's disease; UC, ulcerative colitis; IC, indeterminate colitis.